Bionik Laboratories Corp.
BNKL
$0.00
$0.000.00%
OTC PK
| 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 20.46% | 84.59% | 10.93% | -206.96% | -64.77% |
| Total Depreciation and Amortization | 51.94% | -35.18% | -58.53% | -61.17% | -81.60% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -16.70% | -98.91% | -73.82% | 121.17% | 45.64% |
| Change in Net Operating Assets | 844.56% | 628.40% | -56.15% | 131.59% | 93.15% |
| Cash from Operations | 45.15% | 63.15% | -26.08% | -88.04% | -7.19% |
| Capital Expenditure | -- | 93.60% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 93.60% | -- | -- | -- |
| Total Debt Issued | -- | -- | -95.00% | -9.09% | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 35,614.29% | 57,242.86% | -95.00% | -9.09% | -99.86% |
| Foreign Exchange rate Adjustments | 50.00% | 11.11% | 60.87% | -123.08% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 81.30% | 120.47% | -121.99% | -891.92% | -379.85% |